Canopy Growth stock gains 4.43 percent to EUR 0.66
Published on 10/15/2026 at 21:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPrice move and reporting date
- Tradegate quoted Canopy Growth at 4:28 p.m. CEST on October 15, 2026.
- Canopy Growth scheduled its next results for November 6, 2026.
- Canopy Growth stock costs EUR 0.66 at Lang & Schwarz on October 15, 2026 at 9:01 p.m. CEST, 4.43 percent above the Tradegate quote of October 15, 2026.
- Canopy Growth reported 13.00 percent net revenue growth in the first quarter of fiscal 2027.
Canopy Growth stock gained 4.43 percent against the Tradegate quote of October 15, 2026. At 9:01 p.m. CEST, the stock was trading at EUR 0.66 at Lang & Schwarz after the Xetra session had ended.
The latest company figures provide the operating backdrop. Canopy Growth reported consolidated net revenue of CAD 81.2 million for the first quarter of fiscal 2027, up 13.00 percent from the year-earlier period, in results dated August 7, 2026. The company also reported growth across its cannabis and consumer products businesses.
Revenue growth meets a loss
The revenue increase was broad based but did not eliminate the loss. Standardized financial data put quarterly revenue at CAD 81.165 million and net loss attributable to common shareholders at CAD 14.579 million for the three months ended June 30, 2026. Operating loss was CAD 22.110 million in the same period.
That combination leaves execution central to the share story. Management has described fiscal 2027 as a year for improving profitability, while the reported figures show that revenue growth is progressing ahead of positive earnings.
Range and volume set the frame
Tradegate showed a bid of EUR 0.63 and an ask of EUR 0.64 at 4:29 p.m. CEST on October 15, 2026. The Nasdaq quote was USD 0.74 at 3:04 p.m. ET, with a 52-week range of USD 0.69 to USD 2.38. The current price therefore stood 7.25 percent above the 52-week low and 68.91 percent below the 52-week high.
Trading volume reached 2,247,853 shares against an average of 2,929,473 shares as of October 15, 2026. That is 23.27 percent below the average, keeping the move smaller in volume terms than a high-activity session.
Valuation and November date
Canopy Growth had a market capitalization of USD 311.6 million and a trailing P/E ratio of minus 1.57 as of October 15, 2026. The company does not pay a dividend, according to the quoted market data.
TradingView lists November 6, 2026 as the next earnings date and gives a quarterly revenue estimate of CAD 82.19 million. The date is the next scheduled result in the current calendar, while the estimate is higher than the CAD 81.165 million reported for the latest quarter.
Comparison with peers
Canopy Growth (Nasdaq, USD): plus 4.43 percent, P/E minus 1.57, market capitalization USD 311.6 million
Tilray Brands (Nasdaq, USD): plus 2.39 percent, P/E minus 2.30, market capitalization USD 359.5 million
Aurora Cannabis (Nasdaq, USD): minus 1.32 percent, P/E minus 3.02, market capitalization USD 260.5 million
What the quote says
Canopy Growth's euro quote is above the October 15 Tradegate level used for comparison, while its primary-market valuation remains below the 52-week high by 68.91 percent. The next scheduled results on November 6 will put the 13.00 percent revenue growth and the continuing loss into a new reporting frame.
Canopy Growth was trading at EUR 0.66 at Lang & Schwarz on October 15, 2026 at 9:01 p.m. CEST, 4.43 percent above the Tradegate quote of October 15, 2026. The further course of trading is shown by the continuously updated real-time quote of Canopy Growth stock.
Canopy Growth stock facts
- Company: Canopy Growth Corporation
- ISIN: CA1380357048
- WKN: A3E2FV
- Ticker: CGC
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 9:01 p.m. CEST): EUR 0.66
- Change versus Tradegate quote: plus 4.43 percent
- Tradegate quote (October 15, 2026): EUR 0.63
- Market capitalization: USD 311.6 million (as of October 15, 2026)
- 52-week range: USD 0.69-USD 2.38 (as of October 15, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
- Next earnings date: November 6, 2026
Market context: Market report Nasdaq Composite.
